Recently, GE Healthcare has made frequent moves to invest or cooperate in a number of emerging technology fields that represent the future development direction of healthcare. On December 1, GE Healthcare announced a series of investments and collaborations with Formlabs, CMR Surgical and Decisio Health, which focus on 3D printing, surgical robotics and virtual medical monitoring, respectively. Formlabs is a fast-growing company producing 3D printers based on stereolithography technology at affordable prices.
Working with GE Healthcare, radiologists acquire 3D CT or MRI data through GE Healthcare’s Advantage Workstation, use the AW 3D Suite to output data for 3D printing on Formlabs equipment, or do several View in virtual or augmented reality in seconds. The printed models can help surgeons plan surgeries, enhance physician training, and ease the anxiety of surgical patients.
GE Healthcare disclosed on December 1 that it participated in the US$243 million Series C financing of CMR Surgical in the UK as a minority investor. CMR Surgical was established in 2014 and officially launched the product Versius in September 2018, which is a miniaturized, modular, and low-cost surgical robotic system. Versius obtained EU CE certification in March 2019 and has not yet obtained US FDA certification. CMR Surgical is facilitating the commercialization of the Versius system.
In September 2019, CMR Surgical announced that it had raised a £195 million ($240 million) Series C round, the largest private medtech financing in Europe to date. But GE Healthcare was not mentioned among the investors disclosed at the time. Gustavo Perez-Fernandez, president and CEO of GE Healthcare’s Image Guided Therapies business, said the Versius surgical robotic system, combined with GE Healthcare’s advanced, high-quality imaging and AI capabilities, will be an important guide for surgeons. partner.
According to the latest news, CMR Surgical announced this week the appointment of Per Vegard Nerseth as CEO, replacing former CEO MarTIn Frost, effective January 1, 2020. Nerseth was previously Senior Vice President and General Manager of ABB Robotics and has over 25 years of experience in robotics. Founded in 2013, Decisio Health is the goal of commercializing technology at the University of Texas Health Science Center.
Following GE Healthcare’s investment, the partnership with Decisio Health includes combining GE Healthcare’s digital clinical platform with Decisio visualization software. Combined, clinical teams can fuse potential, retrospective data (such as Electronic medical record data) with real-time patient data (such as blood pressure and lactate levels) to improve clinical decision-making. The exact amount of the investment has not been disclosed.
The center will be an independent non-profit organization headquartered in the greater Boston area with a mission to “advance the development of translational medicine and advanced therapies by shortening the path between research and clinical application,” with one goal being the exploration and development of cell and gene therapies innovative technologies that advance biological discovery and manufacturing and accelerate the development of immunotherapy, cell therapy and gene editing. The consortium program offers access to new manufacturing facilities at discounted rates and will also create a shared innovation space for scientists from across the country to work side-by-side with professional staff.
On November 26, GE announced the launch of the “Edison Developer Program” (Edison Developer Program), which aims to accelerate the application and impact of intelligent applications and developer services in the medical system. Based on Edison, GE’s healthcare security intelligence platform, the project helps healthcare providers more easily access market-ready algorithms and applications by directly integrating these technologies into existing workflows.
For developers, the Edison Developer Program provides a wealth of healthcare services that help them accelerate their ability to innovate to improve operability and clinical outcomes, and enable them to scale and deploy applications across GE Healthcare’s vast customer base program. GE Healthcare solemnly released the “Edison Developer Program” to comprehensively promote the construction of a global smart healthcare ecosystem. GE Healthcare’s life sciences division said it has entered into a strategic R&D and sales partnership with Advanced SoluTIons Life Sciences to begin personalized tissue regeneration.
According to reports, GE Healthcare’s IN Cell Analyzer will be integrated with ASLS’ BioAssemblyBot system to embed cell-level assessments into 3D bioprinting workflows for creating human tissue models. The collaboration plans to design, construct and image living, vascularized 3D tissue in a single process.
Emmanuel Abate, general manager of Genomics & Cellular Research at GE Healthcare’s Life Sciences division, said: “Printing multi-material 3D objects inside microplates allows scientists to effectively move away from traditional 2D man-made monocultures to more accurately reflect native organisms. 3D exploration and cytotoxicity models of biological and disease signatures. The flexibility and precision of BioAssemblyBot combined with the image quality and speed of the IN Cell Analyzer 6500 HS confocal screening platform, the prospect of automating high-content screening in 3D models will become Reality.”
Accurate 3D models could provide a better environment for biopharmaceutical companies to test drugs — with shorter development times — because the models mimic how the human body responds.
The Links: NL10276BC3033E BSM200GB60DLC